In March, CEPI (The Coalition for Epidemic Preparedness) is in London to raise funds for vaccine research and development, as well as promoting their goal of cutting vaccine development by two thirds, to . CEPI asked us if they could use Plague Inc. to help illustrate the vital importance of vaccines to conference delegates and media.
We have created a special version of Plague Inc. called ‘Plague Inc: Ending Pandemics’ for the summit which highlights how early and substantial investments in vaccine R&D, disease surveillance, and global manufacturing can blunt the impact of any future pandemic. If you are going to be attending - keep an eye out for it!
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated nine partnerships to develop vaccines against COVID-19. The programmes are leveraging rapid response platforms already supported by CEPI as well as new partnerships.
Before the emergence of COVID-19, CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).